TrialClinical cancer research : an official journal of the American Association for Cancer Research2014

Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer.

Neil D Gross et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.